HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults
Recruitment status was Active, not recruiting
The purpose of this study is to determine the best way to administer the candidate HIV vaccine, ALVAC HIV-1 (vCP205).
Biological: ALVAC-HIV MN120TMG (vCP205)
|Study Design:||Primary Purpose: Prevention|
|Official Title:||A Phase I Study of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP205, HIV-1 Env/Gag/Pol) in Seronegative Adults Administered (1) Subcutaneously Via Ex Vivo Transfected, Autologous Dendritic Cells, (2) Intradermally, or (3) Intramuscularly|
Healthy adult volunteers are assigned randomly to either a vaccine or placebo group. Injections are received either intramuscularly, intradermally, or by delivery under the skin of the volunteer's own white blood cells which have had dendritic cell reinfusion. Volunteers are vaccinated at 0, 1, 3, and 6 month time points. Volunteers are closely monitored for 1 hour after vaccination and keep a diary of symptoms for 1 week post-immunization. Volunteers undergo leukopheresis at the start of the study and after the last vaccination at Walter Reed Army Medical Center. Volunteers receive compensation benefits.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00013572
|United States, Maryland|
|Walter Reed Army Institute of Research (WRAIR)|
|Rockville, Maryland, United States, 20850|
|Principal Investigator:||Mary Marovich|